Sagimet Biosciences Inc.
NASDAQ:SGMTBiotechnology
Healthcare
$10.11 +1.38%
+$0.09 today
- Market cap
- $711.15M
- Beta
- 3.44
- P/E (TTM)
- -5.0
- EPS (TTM)
- -$1.34
52W Low $4.50High $11.41
Volume 0.93M
Average 1.49M
Income Statement
Follow revenue through to earnings.
Revenue
$0.00
FY 2025 · Annual
Operating Income
-$56.89M
FY 2025 · Annual
Net Income
-$51.04M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 2M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 2M | 0 | 0 |
| Gross Margin | — | — | 100.0% | — | — |
| Research & Development | 19.34M | 24.92M | 19.78M | 38.44M | 39.05M |
| Selling, General & Admin | 4.38M | 6.14M | 12.96M | 16.01M | 17.84M |
| Operating Expenses | 23.72M | 31.06M | 32.74M | 54.45M | 56.89M |
| Depreciation & Amortization | 0 | 130K | 0 | 0 | 0 |
| EBITDA | (24.44M) | (30.37M) | (27.88M) | (45.57M) | (51.04M) |
| EBITDA Margin | — | — | -1393.8% | — | — |
| Operating Income | (23.72M) | (31.06M) | (30.74M) | (54.45M) | (56.89M) |
| Operating Margin | — | — | -1537.0% | — | — |
| Interest Income | 26K | 553K | 2.86M | 8.89M | 5.85M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (723K) | 556K | 2.86M | 8.89M | 5.85M |
| Income Before Tax | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Pre-Tax Margin | — | — | -1393.8% | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.44M) | (30.5M) | (27.88M) | (45.57M) | (51.04M) |
| Net Margin | — | — | -1393.8% | — | — |
| EPS (Basic) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| EPS (Diluted) | (1.10) | (1.38) | (1.53) | (1.45) | (1.58) |
| 22.17M | 22.17M | 18.19M | 31.35M | 32.35M | |
| 22.17M | 22.17M | 18.19M | 31.35M | 32.35M |
SGMT Earnings Waterfall · TTM
NASDAQ:SGMT · Revenue to Net Income
Key Ratios
EPS$-1.35
Gross Margin0.0%
Net Margin0.0%
P/E Ratio-4.8
P/S Ratio0.0
Analysis
$0 of revenue converted into -$43.5M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.35, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Oct 22, 2026 | |
| SC 13G | SC 13G filing | Oct 7, 2026 |
How much revenue does SGMT generate?
Sagimet Biosciences Inc. (SGMT) reported $0.00 of revenue in fiscal 2025.
Is SGMT profitable?
Sagimet Biosciences Inc. (SGMT) reported -$51.04M of net income.
Continue the stock analysis
Jump to another research area for this company.